

EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

Overview of GMP Inspections conducted by Irish Medicines Board

Lorraine Nolan
Acting Inspection Manager
Irish Medicines Board

EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

Agenda

- Overview of IMB's inspection programme
- Inspection Process
- Particular areas of inspection focus
- Common GMP Deficiencies

EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

Overview of GMP Inspection Programme (1)

- 84 authorised manufacturers of medicinal products for human use
- 28 authorised manufacturers of veterinary medicinal products (15 H & V)
- 43 authorised manufacturers of investigational medicinal products
- 7 GMP inspectors and others cross-training

EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

Overview of GMP Inspection Programme (2)

- Routine Inspection every two years as per EU Guideline
- See also under 'Risk Management' below
- Inspections in non – EEA/ non – MRA countries at request of EMEA for centrally authorised products
- Also non – EEA / non – MRA for some nationally authorised products

EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

Overview of GMP Inspection Programme (3)


- Quality Risk Management
 - Early change to two year inspection frequency unlikely
 - QRM applied to deciding on re - inspection at shorter interval where significant non – compliances identified
 - Quality of manufacturer's approach to QRM will be closely examined

EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

Overview of GMP Inspection Programme (4)




Number of site inspections 2006-2008

Year	API National	API Foreign	FP National	FP 3rd Country
2006	8	1	72	10
2007	10	1	70	9
2008	8	4	81	18



- EU Regulatory Network**
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia
- Overview of API Inspection Programme (1)**
- No requirement for Active Substance manufacturers to be authorised
 - However, all inspected regularly in relation to requests for GMP certification
 - API inspections non-EEA/non-MRA countries at request of EDQM / EMEA

- EU Regulatory Network**
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia
- Overview of API Inspection Programme (2)**
- Commenced in the mid 1990s
 - Limited number of API sites and IMB Inspectors
 - Now, a rolling program of API inspections is in place at 2 to 3 year frequency for 'routine'
 - Provision to conduct non-routine inspections:
 - Significant change to premises
 - Introduction of new API, technology, equipment





EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia




REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKCIJE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

National Legislation (1)

- Medicinal Products (Control of Manufacture) Regulations 2007**
http://www.dohc.ie/legislation/statutory_instruments/pdf/si20070539.pdf?direct=1
- Effective July 23rd 2007 - Consolidates requirements from
-Title IV of Directive 2001/83/EC (as amended by Directive 2004/27/EC) which relate to the manufacture and importation of medicinal products for human use.



EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia




REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKCIJE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

National Legislation (2)

- Article 13 of Directive 2001/20/EC and Chapter 3 of Directive 2005/28/EC** which relate to the manufacture and importation of investigational medicinal products.
- Directive 2003/94/EC** which lays down the principles and guidelines in respect of manufacture of medicinal products (including investigational medicinal products) for human use.
- One set of manufacturing regulations for human medicines and IMPs



EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia




REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKCIJE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

National Legislation (3)

- 2001/82/EC - Veterinary Medicines**
-Transposed into Irish law in European Communities (Animal Remedies) (No. 2) Regulations 2007 (superceded Regulations from November 2005)

<http://www.agriculture.gov.ie/legislation/SI2007/SI786-2007.pdf>



EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia




REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKCIJE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

Inspection Focus & Deficiencies (1)

- Critical**
A failure that indicates a significant risk that a product could or would be harmful to the patient, or a failure that has produced a harmful product
- Major**
A non critical failure which indicates a significant departure from GMP
- Other**
A deficiency which cannot be classified as either critical or major, but which indicates a departure from GMP



EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia




REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKCIJE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

Inspection Focus & Deficiencies (2)

3 Critical Deficiencies issued 2006-2008

- In 2 cases: A combination of multiple major deficiencies in EU GMP compliance resulting in lack of confidence in the quality management system
- In 1 case: Deficiencies in a number of areas impacting Sterility Assurance had a cumulative potential to lead to a significant risk of producing a product which is harmful to the veterinary patient.



EU Regulatory Network
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia




REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKCIJE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

Inspection Focus & Deficiencies (3)

Overview of Major Deficiencies 2006-2008

Section of EU GMP Guide	%
Quality Management	24
Personnel	7
Premises & Equipment	17
Documentation	5
Production	34

 **EU Regulatory Network**
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

 
REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKTE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

Inspection Focus & Deficiencies (4)

Overview of Major Deficiencies 2006-2008

Section of EU GMP Guide	%
Quality Control	12
Contract Manufacture & Analysis	0
Complaints & Recall	1
Self Inspection	0

 **EU Regulatory Network**
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

 
REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKTE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

Inspection Focus & Deficiencies (5)

Overview of Major Deficiencies 2006-2008

- **Production**
 - Inadequate process validation
 - Demonstration that the manufacturing process is not adequately controlled
 - Inadequate precautions to prevent mix-ups
 - Demonstration of poor manufacturing practice
 - Inadequate cleaning validation
 - Inadequate control of starting materials

 **EU Regulatory Network**
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

 
REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKTE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

Inspection Focus & Deficiencies (6)

Overview of Major Deficiencies 2006-2008

- **Quality Management**
 - Inadequate Procedure for Product Release
Not apparent how it is ensured that the release procedure is in compliance with the Marketing Authorisation
Definition of responsibilities/procedure for product release poorly defined
 - Non-conformance/deviations not reported
 - Inadequate handling and investigation of non-conformances/ deviations

 **EU Regulatory Network**
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

 
REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKTE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

Inspection Focus & Deficiencies (7)

Overview of Major Deficiencies 2006-2008

- **Quality Management**
 - Inadequate handling of Change Control
Procedure not followed in all cases
Change Controls not adequately assessed with regard to validation requirements
 - Absence of a system for performing Product Quality Reviews

 **EU Regulatory Network**
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

 
REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKTE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

Inspection Focus & Deficiencies (8)

Overview of Major Deficiencies 2006-2008

- **Premises & Equipment**
 - Standard of housekeeping, and finish and design of GMP areas not acceptable
Peeling paintwork, loose and flaking plaster, dead flies
Walls/ceilings not flush
Ledges on walls & doors
Gaps & holes in ceilings and walls of GMP areas
Floors not sloping to drain
Inadequate dust extraction
 - Cleaning procedures not sufficient to prevent contamination/ cross contamination

 **EU Regulatory Network**
Challenges and Opportunities for Croatia
5th ALMP Anniversary
13-14 November 2008, Rijeka - Croatia

 
REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIGENDNE I MEDICINSKE PRODUKTE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

Inspection Focus & Deficiencies (9)

Overview of Major Deficiencies 2006-2008

- **Premises & Equipment**
 - Design of the manufacturing facility not adequate to ensure product manufactured in compliance with GMP
 - Production did not occur in a logical order e.g. raw materials for processing were brought into the facility through a wash room area
 - Design of the GMP areas not acceptable e.g. ceiling was not a sealed integral unit, processing pipe-work was not integrated into the walls
 - Processing operations were conducted in an open environment with no added containment measures



EU Regulatory Network

Challenges and Opportunities for Croatia
5th ALMP Anniversary

13-14 November 2008, Rijeka - Croatia



REPUBLIKA HRVATSKA
REPUBLIC OF CROATIA
AGENCIJA ZA LIJEKOVE I MEDICINSKE PROIZVODE
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

- Thank-you to the Croatian Agency for Medical Products and Medical Devices & EMA for the invitation
- Thank you for your attention
- Questions are welcome
- Queries on the GMP inspection programme are welcome and can be submitted to compliance@imb.ie